POLR2L and prostate carcinoma: The high contributions of POLR2L to the transcriptomic alteration in all three types of thyroid cancer samples, as measured with the Transcriptomic Distance (Figure 5c), indicate that it might be a good target for anti-thyroid cancer gene therapy, as was suggested for prostate cancer [113].